^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    USP6 mutation

    i
    Other names: USP6, Ubiquitin Specific Peptidase 6, Ubiquitin Carboxyl-Terminal Hydrolase 6, Tre-2, TRE17, HRP1, Ubiquitin Specific Peptidase 6 (Tre-2 Oncogene), Ubiquitin Specific Protease 6 (Tre-2 Oncogene), Ubiquitin-Specific-Processing Protease 6, Deubiquitinating Enzyme 6, Ubiquitin Thioesterase 6, TBC1D3 And USP32 Fusion, Proto-Oncogene TRE-2, TRESMCR, Tre2, TRE2, TRE Oncogene, Smith Magenis Syndrome Chromosome Region, Ubiquitin-Specific Protease USP6, Ubiquitin Thiolesterase 6, Hyperpolymorphic Gene 1, Tre-2 Oncogene, USP6-Short
    Entrez ID:
    9098
    almost4years
    Association of USP6 mutation with tumor mutation burden and survival in melanoma patients treated with immune checkpoint inhibitors (AACR 2022)
    Immune checkpoint inhibitors (ICIs) including pembrolizumab, nivolumab, ipilimumab have been approved by FDA. This study shows that USP6 mutation may serve as a potential positive biomarker of ICIs in melanoma since it correlated with higher TMB, the up regulation of M1 macrophages, follicular helper T cells and the down regulation of differential neutrophil.
    Clinical • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • USP6 (Ubiquitin Specific Peptidase 6)
    |
    TMB-H • USP6 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)